While the ablation of C-Raf from these cells inhibited tumor development, B-Raf did not show the same effect, indicating that the loss of C-Raf cannot be compensated by other Raf isoforms in K-RASG12V-addicted NSCLCs [83]. This evidence concerns the gene BRAF and neoplasm.